exRNAdisease

Entry Detail

---



General Information

Database ID: exR0359507 RNA Name: AHNAK RNA Type: mRNA Chromosome: chr11 Starnd: - Coordinate: Start Site(bp): 62433542 End Site(bp): 62556235 External Links: ENSG00000124942

Disease Information

Disease Name: Amyotrophic Lateral Sclerosis Disease Category: Nervous System Diseases MeSH ID: D000690 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Amyotrophic Lateral//Gehrig's Disease//Gehrig Disease//Gehrigs Disease//Charcot Disease//Motor Neuron Disease, Amyotrophic Lateral Sclerosis//Lou Gehrig's Disease//Lou-Gehrigs Disease//Disease, Lou-Gehrigs//ALS - Amyotrophic Lateral Sclerosis//ALS Amyotrophic Lateral Sclerosis//Lou Gehrig Disease//Amyotrophic Lateral Sclerosis, Guam Form//Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1//Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1//Guam Form of Amyotrophic Lateral Sclerosis//Guam Disease//Disease, Guam//Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam//Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam//Amyotrophic Lateral Sclerosis With Dementia//Dementia With Amyotrophic Lateral Sclerosis

Expression Detail

GEO ID: GSE121519 Description: Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. Experimental Design: Disease vs Control Case Disease Type: Amyotrophic Lateral Sclerosis Case Disease SubType: NA Case Sample: Amyotrophic Lateral Sclerosis Control Sample: Healthy Number of Case: 4 Number of Control: 4 Number of Samples: 8

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand SRRM2 chr16 2752626 2772538 + C15orf39 chr15 75195643 75212169 + DGKI chr7 137381037 137847092 - LRRC8A chr9 128882112 128918039 + PPP1R8 chr1 27830782 27851676 + COMT chr22 19941733 19969975 + SLC16A1 chr1 112911847 112957013 - RBM33 chr7 155644451 155781485 + PSMD8 chr19 38374536 38383824 + PSMB1 chr6 170535120 170553307 - DNMT3A chr2 25227855 25342590 - PABPC3 chr13 25095868 25099254 + TOR1AIP2 chr1 179839967 179877803 - APP chr21 25880550 26171128 - MPZL1 chr1 167721192 167791919 + DCAF8 chr1 160215715 160262549 - FBXO31 chr16 87326987 87392142 - SORL1 chr11 121452314 121633763 + RABEP1 chr17 5282265 5386340 + ARL2BP chr16 57245259 57253635 + HUWE1 chrX 53532096 53686728 - RACK1 chr5 181236897 181248096 - KDM6A chrX 44873177 45112602 + CCNG2 chr4 77157207 77433388 + TMEM132A chr11 60924463 60937159 + PPP6R1 chr19 55229779 55259017 - R3HCC1 chr8 23270120 23296279 + TTC38 chr22 46267961 46294008 + MFN2 chr1 11980181 12013514 + MORF4L2 chrX 103675496 103688158 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002470.2 chr22 20979462 20998121 + AC010327.5 chr19 55216660 55221616 + AD000090.1 chr19 35557956 35581954 + AL139385.1 chr13 110613082 110616353 - LINC00174 chr7 66376044 66493566 - RMRP chr9 35657751 35658018 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE121519 Sample Source: Cerebrospinal Fluid Source Fraction: Exosome Platform: GPL18573 Method: NGS Num of detected RNA Type: 2 Num of detected RNAs of this Type: 17787 Sample treatment protocol: Up to 1 mL of human CSF was centrifuged at 2,000×g for 5 min and 10, 000×g for 20 min for supernatant. RNA Extract protocol: Supernatant from final centrifugation was applied to exoRNeasy spin column and RNA was extracted. RNA library preparation protocol: Whole cDNA amplification was performed with SMART-seq v4 Ultra Low Input RNA Kit. Illumina library was constructed with Nextera XT DNA Library Prep Kit.

Reference

PMID: 30630471 Title: Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid Author: Otake K, Kamiguchi H, Hirozane Y Journal: BMC Med Genomics. 2019 Jan 10;12(1):7. Description: The main purpose of this study is to established the methodology of comprehensive analysis of exosomal mRNAs in CSF by a highly sensitive next-generation sequencing.